Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515728 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL15977917 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL7914906 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL788641 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL25206528 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL198354 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL23234144 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL18970877 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL23016820 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL31314689 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3771337-B1 | ANTIMICROBIAL COMPOSITION | PROCTER & GAMBLE (US) | 2026-04-29 | — | — | EP | claimed |
| CN-120082629-A | Reagent for detecting creatine kinase, kit and application | 湖南师范大学 | 2025-06-03 | — | — | CN | claimed |
| EP-4507722-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | Bluewillow Biologics, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| CN-119303068-A | Acinetobacter baumannii outer membrane protein liposome vaccine, and preparation method and application thereof | 中国人民解放军陆军军医大学 | 2025-01-14 | — | — | CN | claimed |
| US-12076397-B2 | Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-09-03 | — | — | US | claimed |
| CN-118382704-A | Method for reducing measurement error caused by haemoglobin | 东洋纺株式会社 | 2024-07-23 | — | — | CN | claimed |
| CN-117589998-A | Quantitative detection kit for insulin-like growth factor I variants | 融智生物科技（青岛）有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-117589997-A | Quantitative detection method for IGF-1 variant | 融智生物科技（青岛）有限公司 | 2024-02-23 | — | — | CN | claimed |
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | claimed |
| CN-117310182-A | Sample processing kit for detecting Cys C by MALDI-TOF MS and application thereof | 融智生物科技（青岛）有限公司 | 2023-12-29 | — | — | CN | claimed |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| US-20070281298-A1 | Procedure for the Determination of Fragmentation of Dna in Animal Sperm | GOSALVEZ BERENGUER JAIME | 2007-12-06 | — | — | US | claimed |
| US-7186522-B2 | Using detergents to reduce artifacts during staining of biological samples; medical diagnostics and cervical cancer | CYTYC CORPORATION (US) | 2007-03-06 | — | — | US | claimed |
| US-20070003998-A1 | Papanicolau staining process | THIRD WAVE TECHNOLOGIES, INC. | 2007-01-04 | — | — | US | claimed |
| EP-1710320-A1 | A METHOD FOR DETERMINATION OF DNA FRAGMENTATION IN ANIMAL SPERM CELL | Universidad Autónoma de Madrid (ES) | 2006-10-11 | — | — | EP | claimed |
| US-20040191854-A1 | Papanicolau staining process | CYTYC CORPORATION | 2004-09-30 | — | — | US | claimed |
| US-6692537-B1 | ENZYME OF 2-ELECTRON OXIDOREDUCTASE TYPE IN THE PRESENCE OF AT LEAST ONE DONOR FOR THE SAID ENZYME AND AT LEAST ONE NONIONIC FATTY SUCRONAMIDE | L'OREAL S.A. (FR) | 2004-02-17 | — | — | US | claimed |
| US-20030134420-A1 | Methods and compositions for gene delivery | IMMUNE RESPONSE CORPORATION, THE | 2003-07-17 | — | — | US | claimed |
| WO-2001060415-A1 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | THE IMMUNE RESPONSE CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | DPM1, ERG28, POLR1C | EPHX2 354/4885MEN1 969/4885KMT2A 2701/4885 |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | EPHX2 1655/4885MEN1 624/4885KMT2A 2755/4885 |
| US-12076397-B2 | Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration | DBI, DLAT, ABHD5 | EPHX2 851/4885MEN1 2231/4885KMT2A 1846/4885 |
| US-20030134420-A1 | Methods and compositions for gene delivery | POLRMT, NUP205, POLM | EPHX2 3458/4885MEN1 3705/4885KMT2A 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.